GSK (GSK) announced that AREXVY, Respiratory Syncytial Virus Vaccine, Adjuvanted,, is now available in the US at all major retail pharmacies. In June, the Advisory Committee on Immunization Practices, ACIP, recommended that persons 60 years of age and older may receive a single dose of RSV vaccine, using shared clinical decision making. Shared clinical decision making empowers patients, in consultation with their healthcare providers, to decide whether RSV vaccination is appropriate for them. AREXVY is indicated for the prevention of RSV-lower respiratory tract disease, LRTD, in individuals aged 60 years and older. Companies in the retail pharmacy space invlude CVS Health (CVS), Rite Aid (RAD), and Walgreens Boots Alliance (WBA).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GSK:
- GSK sues Pfizer, alleging infringement of RSV vaccine patents
- GSK price target lowered to 1,300 GBp from 1,400 GBp at JPMorgan
- CureVac doses first patient in Phase 2 study of COVID-19 vaccine candidates
- GSK reports FDA grants expanded approval of Jemperli
- GlaxoSmithKline (GSK) Declares Q4 Dividend: Important Details for Shareholders